Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study Of Tasocitinib In Dry Eye Subjects

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT01226680
First received: October 20, 2010
Last updated: December 21, 2010
Last verified: December 2010

October 20, 2010
December 21, 2010
December 2010
October 2011   (final data collection date for primary outcome measure)
  • Change in length of wetting of Schirmer test strip without anesthesia from baseline [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Change in Ocular Surface Disease Index's Environmental Trigger (OSDI-ET) subscale score from baseline [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01226680 on ClinicalTrials.gov Archive Site
  • Systemic safety: adverse events, clinical laboratory; and vital signs [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Ocular tolerability and safety: incidence and severity of ocular adverse events during the study (ophthalmic examination, ocular tolerability assessment and/ or adverse events spontaneously reported) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Schirmer test without anesthesia: Change in length of wetting from baseline at Days 7, 14, 28, and Week 8; Response rate (percentage of subjects who achieve ≥10mm wetting) at Days 7, 14, 28, and Weeks 8 and 12; Response rate (percentage of [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • subjects who achieve increase of ≥10mm wetting) at Days 7, 14, 28, and Weeks 8 and 12; Time to achievement of change from baseline of ≥10mm wetting;Time to achievement of ≥10mm wetting [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Corneal staining:Change from baseline at Days 7, 14, 28 and Weeks 8 and 12;Response rate (percentage of subjects who demonstrate 100% clearing of corneal staining) at Days 7, 14, 28 and Weeks 8 and 12;Time to achievement of 100% clearing of corneal [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • staining [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Ocular Surface Disease Index (OSDI): Change in the OSDI total score and three subscale scores (the Ocular Symptoms, Vision-Related Function, and Environmental Triggers) from baseline at Days 7, 14, 28, and Weeks 8 and 12 (except ET subscale [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • score); Response rate (percentage of subjects who demonstrating ≥10 unit decrease in OSDI total score) at Days 7, 14, 28, and Weeks 8 and 12; Time to achievement of ≥10 unit decrease in OSDI total score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Modified Ocular Comfort Index (mOCI): Change in the OCI score, the Dry Eye Symptoms (DES) and Symptom Interference (SI) subscales scores from baseline at Days 7, 14, 28 and Weeks 8 and 12; OCI Response rate (percentage of subjects who demonstrating [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • ≥3 point decrease from baseline in the OCI score) at Days 7, 14, 28, and Weeks 8 and 12; Time to achievement of ≥3 point decrease from baseline in the OCI score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study Of Tasocitinib In Dry Eye Subjects
A Phase II, Randomized, Double Masked, Parallel Group, Vehicle Controlled, Multiple-Dose Study Of Tasocitinib (CP-690,550) In Subjects With Dry Eye Disease

This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease. Both subjective and objective clinical endpoints will be measured for a duration of 12-week treatment.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Keratoconjunctivitis Sicca
  • Drug: Tasocitinib
    0.005% QD for 12 weeks
  • Drug: Tasocitinib
    0.003% QD for 12 weeks
  • Drug: vehicle for Tasocitinib
    vehicle QD for 12 weeks
  • Experimental: Tasocitinib 0.005% QD
    Intervention: Drug: Tasocitinib
  • Experimental: Tasocitinib 0.003% QD
    Intervention: Drug: Tasocitinib
  • Placebo Comparator: Vehicle for Tasocitinib
    Intervention: Drug: vehicle for Tasocitinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
240
November 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females aged 18 years or older at time of consent
  • Diagnosis of dry eye disease, characterized by subjective symptoms of dry eye for at least 6 months, Schirmer test without anesthesia: =>1 mm and =<7 mm, sum of corneal fluorescein staining score of =>4 (NEI Scale), and subject grading total score of => 23 on the OSDI

Exclusion Criteria:

  • Planned initiation of, or changes to, concomitant medication that could affect dry eye within 30 days of the Screening visit or during study
  • Ocular disorders that may confound interpretation of study results such as significant corneal surface disease not caused by dry eyes, abnormal corneal sensitivity, abnormal tear spreading, including but not limited to the following: abnormal lid function, lid position, or blink rate, that in the opinion of the investigator is clinically significant, history of herpetic keratopathy
  • Lacrimal punctal occlusion (plugs or cautery) within 2 months of the Screening visit
  • Contact lens wear within 2 weeks of the Screening visit and/or during study participation.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01226680
A3921066
No
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP